Skip to main content
Equibles
BRNS logo

BRNS · Barinthus Biotherapeutics plc. · Metrics

Track BRNS — free

Use BRNS with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research BRNS.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$0.74 -0.02 (-2.50%) At close · Sep 8
Rebalance outlook locked
Market Cap
$30.23M
Shares
40.85M
Volume · Sep 8 378.15K Avg daily vol (3M) 57.87K

BRNS metrics

63 of 122 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$0.74
Market cap
$30.23M

Price action

20 metrics
Price change (1W)
-3.3%
Price change (30D)
—
Price change (3M)
+2.2%
Price change (6M)
+31.0%
Price change (YTD)
+5.7%
Price change (1Y)
-39.1%
Trailing year
Price change (5Y)
—
52-week high
$1.58
52-week low
$0.54
Change from 52-week high
-53.2%
Change from 52-week low
+37.0%
Annualized volatility
78.8%
Annualized volatility (3M)
76.1%
Beta
0.8
RSI (14D)
60.2
Price vs SMA 50
+17.6%
Price vs SMA 200
+12.4%
Avg volume (3M)
57,868
Relative volume
6.5
Average dollar volume
$39,001

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
40.85M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
—
P / book
0.5
reciprocal yield 188.8%
FCF yield
-87.4%
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-138.1%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2025-05-07

Profitability

9 metrics
Gross margin
—
Operating margin
—
Trailing 12 months
Net margin
—
Gross profit (TTM)
—
Operating profit (TTM)
−$43.73M
Net income (TTM)
−$41.76M
Trailing 12 months
Diluted EPS (TTM)
$-1.03
FCF margin
—
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
$-1.07
EBITDA per diluted share (TTM)
$-0.99
Net income per diluted share (TTM)
$-1.02
Operating cash flow per diluted share (TTM)
$-0.65
Free cash flow per diluted share (TTM)
$-0.65
Capital expenditures per diluted share (TTM)
$0.00
R&D per diluted share (TTM)
$0.41
Stock compensation per diluted share (TTM)
—
Book value per share
$1.82

Growth

11 metrics
Revenue growth YoY
-100.0%
Year over year
Net income growth YoY
—
Revenue (TTM)
—
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+1.3%
Year over year · more shares
Revenue CAGR (3Y)
—
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-73.2%
Return on assets
-51.0%
Debt / equity
—
Current ratio
5.5
EBITDA (TTM)
−$40.24M
Free cash flow (TTM)
−$26.43M
Quick ratio
5.5
Interest coverage
-825.0
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Cash & equivalents
$59.30M
Total assets
$81.89M
Total debt
—

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$26.43M
Capital expenditures (TTM)
$0
R&D (TTM)
$16.84M
SG&A (TTM)
—
Stock compensation (TTM)
$1.27M
R&D / revenue
—
Stock compensation / revenue
—

Ownership (13F)

9 metrics
13F filers
15
13F filer change QoQ
+1
Institutional ownership
22.5%
Conviction holders (share of 13F filers)
6.7%
Crowding (high-turnover and private-fund holders)
0.9%
Private-fund adviser ownership
0.8%
Active holders' share change QoQ
-2.2%
Holder tenure
10.8
Price vs estimated holder cost
-84.1%

Ownership (registered funds)

1 metrics
Index-fund ownership
0.0%

Short interest

3 metrics
Short interest
—
Latest settlement
Days to cover
—
Short-squeeze score
—

Insider activity

2 metrics
Net insider buying (90D)
—
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
—
Key facts CIK 1828185 CUSIP 91864C107 Visit website Investor relations